MA52364A - Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale - Google Patents
Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumoraleInfo
- Publication number
- MA52364A MA52364A MA052364A MA52364A MA52364A MA 52364 A MA52364 A MA 52364A MA 052364 A MA052364 A MA 052364A MA 52364 A MA52364 A MA 52364A MA 52364 A MA52364 A MA 52364A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- dna
- tumor therapy
- dual atm
- atm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810359447.6A CN110386932A (zh) | 2018-04-20 | 2018-04-20 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
US201862665296P | 2018-05-01 | 2018-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52364A true MA52364A (fr) | 2021-03-03 |
Family
ID=68283636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052364A MA52364A (fr) | 2018-04-20 | 2019-04-17 | Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220315606A1 (fr) |
EP (2) | EP4327877A3 (fr) |
JP (1) | JP7366996B2 (fr) |
KR (1) | KR20210027251A (fr) |
CN (2) | CN110386932A (fr) |
BR (1) | BR112020021323A2 (fr) |
CA (1) | CA3096732A1 (fr) |
MA (1) | MA52364A (fr) |
MX (1) | MX2020010942A (fr) |
SG (1) | SG11202010212RA (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016057931A1 (fr) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy |
WO2019201283A1 (fr) | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale |
AU2020322026A1 (en) * | 2019-07-30 | 2022-02-03 | Xrad Therapeutics, Inc. | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy |
WO2021098734A1 (fr) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | Composé de quinolinopyrrolidone substitué utilisé en tant qu'inhibiteur d'atm et son application |
WO2021098813A1 (fr) * | 2019-11-22 | 2021-05-27 | 南京明德新药研发有限公司 | Composés spiro pyrimidopyrrole et leurs dérivés en tant qu'inhibiteurs de la protéine dna-pk |
CN113121538B (zh) * | 2019-12-31 | 2023-04-21 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2303890A4 (fr) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | Inhibiteurs de phosphatidylinositol 3 kinase |
CN102256966B (zh) * | 2008-10-17 | 2016-02-10 | 白头生物医学研究所 | 可溶性mTOR复合物和其调节剂 |
WO2010139747A1 (fr) | 2009-06-04 | 2010-12-09 | Novartis Ag | Composés 1h-imidazo [4,5-c] quinolinone utiles pour le traitement des maladies prolifératives |
JP2013512952A (ja) | 2009-12-07 | 2013-04-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インドールコアを含有する複素環化合物 |
RU2013130907A (ru) | 2010-12-06 | 2015-01-20 | Пирамал Энтерпрайзис Лимитед | Замещенные имидазохинолиновые производные |
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
AR089929A1 (es) | 2012-02-10 | 2014-10-01 | Actelion Pharmaceuticals Ltd | Proceso para manufacturar un derivado de naftiridina |
CN107383009B (zh) | 2012-06-13 | 2020-06-09 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
CN103936762B (zh) * | 2013-01-17 | 2016-02-24 | 上海汇伦生命科技有限公司 | 吗啉并喹啉类化合物,其制备方法和用途 |
CN103880844A (zh) * | 2014-04-09 | 2014-06-25 | 彭正中 | 一种喹啉酮类新化合物及其制备方法与用途 |
NO2714752T3 (fr) * | 2014-05-08 | 2018-04-21 | ||
CN105461711B (zh) * | 2014-06-17 | 2018-11-06 | 正大天晴药业集团股份有限公司 | 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
CN105461712B (zh) * | 2014-06-17 | 2019-01-29 | 上海嘉坦医药科技有限公司 | 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
KR102495840B1 (ko) * | 2014-06-17 | 2023-02-03 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체 |
EP3159342B1 (fr) * | 2014-06-17 | 2020-08-05 | Cisen Pharmaceutical Co., Ltd. | Analogue de pyridino [1,2-a]pyrimidone utilisé en tant qu'inhibiteur de pi3k/mtor |
WO2016044662A1 (fr) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Composés de pyridone substituée par pyrazolyl en tant qu'inhibiteurs de sérine protéase |
PT3560924T (pt) * | 2015-04-02 | 2021-07-02 | Merck Patent Gmbh | Imidazolinilquinolinas e a sua utilização como inibidores da cinase atm |
WO2016186453A1 (fr) | 2015-05-20 | 2016-11-24 | Kainos Medicine, Inc. | Dérivés de quinoléine à utiliser en tant qu'inhibiteurs de bromodomaine |
GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US11427561B2 (en) | 2016-01-20 | 2022-08-30 | Biogen Ma Inc. | IRAK4 inhibiting agents |
WO2017162611A1 (fr) * | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Composés quinoline-3-carboxamide et leur utilisation pour traiter le cancer |
GB201608227D0 (en) * | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
BR112021005989A2 (pt) * | 2018-09-30 | 2021-06-29 | Medshine Discovery Inc. | derivados de quinolino-pirrolidin-2-ona e aplicação dos mesmos |
-
2018
- 2018-04-20 CN CN201810359447.6A patent/CN110386932A/zh active Pending
-
2019
- 2019-04-17 MA MA052364A patent/MA52364A/fr unknown
- 2019-04-17 MX MX2020010942A patent/MX2020010942A/es unknown
- 2019-04-17 KR KR1020207033463A patent/KR20210027251A/ko unknown
- 2019-04-17 SG SG11202010212RA patent/SG11202010212RA/en unknown
- 2019-04-17 JP JP2021506031A patent/JP7366996B2/ja active Active
- 2019-04-17 CN CN201980040733.9A patent/CN112469720B/zh active Active
- 2019-04-17 BR BR112020021323-3A patent/BR112020021323A2/pt unknown
- 2019-04-17 EP EP23202655.9A patent/EP4327877A3/fr active Pending
- 2019-04-17 CA CA3096732A patent/CA3096732A1/fr active Pending
- 2019-04-17 EP EP19787882.0A patent/EP3784671B1/fr active Active
-
2020
- 2020-10-19 US US17/074,425 patent/US20220315606A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021522316A (ja) | 2021-08-30 |
CN112469720A (zh) | 2021-03-09 |
MX2020010942A (es) | 2021-01-15 |
EP4327877A3 (fr) | 2024-04-24 |
EP4327877A2 (fr) | 2024-02-28 |
US20220315606A1 (en) | 2022-10-06 |
CN112469720B (zh) | 2024-03-29 |
CA3096732A1 (fr) | 2019-10-24 |
EP3784671B1 (fr) | 2023-10-11 |
EP3784671A4 (fr) | 2021-11-17 |
EP3784671A1 (fr) | 2021-03-03 |
SG11202010212RA (en) | 2020-11-27 |
AU2019254980A1 (en) | 2020-12-03 |
BR112020021323A2 (pt) | 2021-01-19 |
JP7366996B2 (ja) | 2023-10-23 |
CN110386932A (zh) | 2019-10-29 |
KR20210027251A (ko) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52364A (fr) | Inhibiteurs doubles d'atm et d'adn-pk pour une utilisation en thérapie antitumorale | |
MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MA52963A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
MA46995A (fr) | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase | |
MA52542A (fr) | Thérapie cellulaire adoptive | |
MA50912A (fr) | Inhibiteurs d'acss2 et leurs procédés d'utilisation | |
SG11202104010PA (en) | Rgmc-selective inhibitors and use thereof | |
IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
IL275951A (en) | Vectors that evade the immune system and their use for gene therapy | |
ZA202000904B (en) | Mpo inhibitors for use in medicine | |
IL289542A (en) | Dual atm and dna-pk inhibitors for antitumor therapy use | |
IL275132A (en) | C5AR inhibitors for use in the treatment of iatrogenic pain caused by chemotherapy | |
MA55504A (fr) | Anticorps dirigés contre le liraglutide et leur utilisation | |
EP3806692C0 (fr) | Dispositif de retenue pour cartes et/ou billets de banque | |
IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
SG11202108832XA (en) | Anti-ang2 antibody and use thereof | |
AU2019254980B2 (en) | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | |
GB201914765D0 (en) | Inhibitors of clec14a for use in the treatment of clear cell renal cell carcinoma | |
MA55781A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |